Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics

Core Insights - AbbVie reported revenue of $14.46 billion for the quarter ended September 2024, reflecting a year-over-year increase of 3.8% and surpassing the Zacks Consensus Estimate by 1.29% [1] - The earnings per share (EPS) for the quarter was $3.00, compared to $2.95 in the same quarter last year, resulting in an EPS surprise of 2.74% over the consensus estimate of $2.92 [1] Revenue Performance by Product - Creon (US): $338 million, exceeding the estimated $303.41 million, with a year-over-year increase of 10.8% [3] - Rinvoq (International): $444 million, above the estimated $433.05 million, showing a significant year-over-year increase of 43.7% [3] - Rinvoq (US): $1.17 billion, surpassing the $1.12 billion estimate, with a year-over-year growth of 46.1% [3] - Skyrizi (International, Immunology): $427 million, slightly above the estimated $426.56 million, representing a 70.1% year-over-year increase [3] - Total Neuroscience Revenue: $2.36 billion, exceeding the $2.32 billion estimate, with a year-over-year increase of 15.7% [3] - Total Aesthetics Revenue: $1.24 billion, below the estimated $1.34 billion, showing no year-over-year change [3] - Total Immunology Revenue: $7.05 billion, above the estimated $6.86 billion, with a year-over-year increase of 3.9% [3] - Total Eye Care Revenue: $525 million, slightly below the estimated $529.68 million, reflecting a year-over-year decline of 13.2% [3] - Total Linzess/Constella Revenue: $234 million, below the estimated $265.25 million, with a year-over-year decrease of 18.8% [3] - Total Qulipta Revenue: $176 million, exceeding the estimated $167.27 million, with a year-over-year increase of 33.3% [3] - Other Neuroscience Revenue: $84 million, above the estimated $63 million, showing a year-over-year increase of 37.7% [3] Stock Performance - AbbVie shares have returned -3.8% over the past month, contrasting with the Zacks S&P 500 composite's +1.8% change, indicating underperformance relative to the broader market [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [4]